Azelaic Acid for Women Over 65: Off-Label Uses, Safety, and What the Evidence Actually Shows

What Azelaic Acid Actually Is and Why Women Over 65 Are Prescribed It

Azelaic acid is a naturally occurring dicarboxylic acid found in wheat, rye, and barley. At prescription concentrations of 15% and 20%, it does four things simultaneously: it inhibits tyrosinase (the enzyme that drives melanin synthesis), it has mild comedolytic properties, it reduces inflammatory cytokine activity, and it is selectively toxic to hyperactive melanocytes while leaving normal melanocytes largely undisturbed.

That last property is particularly relevant for older women. After menopause, melanocyte behavior becomes erratic. Estrogen normally helps regulate melanocyte-stimulating hormone signaling, and as estrogen declines sharply, many women develop new or worsening pigmentary problems: melasma that appears or worsens around perimenopause, solar lentigines that multiply rapidly, and post-inflammatory marks that take far longer to fade than they did at 35.

Dermatologists reach for azelaic acid in this group for a specific reason: it is gentler than hydroquinone on compromised skin. Hydroquinone at 4% remains the standard depigmenting agent, but it carries a real risk of ochronosis with prolonged use and can be irritating on skin that has already lost elasticity and barrier function. Azelaic acid does not cause ochronosis. That matters at 65 and beyond.

FDA Approval vs. Off-Label Reality

The FDA approvals for azelaic acid cover two specific indications: mild-to-moderate inflammatory acne vulgaris (20% cream) and mild-to-moderate rosacea (15% gel and 15% foam). Melasma, solar lentigines, general photoaging hyperpigmentation, and periocular darkening are all off-label. Off-label prescribing is legal and common; dermatologists routinely prescribe azelaic acid for pigmentation because the mechanism is well understood and the safety data from the approved indications is reassuring.

A woman over 65 using azelaic acid for melasma is using it off-label, and she should know that. The trials supporting that use are smaller and mostly conducted in younger women of childbearing age. What this means in practice: the efficacy data is reasonable but not as strong as the rosacea data, and nobody has run a large RCT specifically in postmenopausal skin.

The Postmenopausal Skin Problem That Changes Everything

Postmenopausal skin is not simply "older skin." It is hormonally depleted skin, and that matters pharmacologically.

Estrogen receptors are expressed throughout the epidermis and dermis. After menopause, the loss of estrogen reduces collagen synthesis by approximately 30% within the first five years, thins the stratum corneum, reduces sebum production, and decreases skin hydration. The practical result: skin in women over 65 is thinner, drier, more permeable, and slower to recover from irritation than skin in premenopausal women.

This affects azelaic acid in two ways. First, percutaneous absorption may be slightly higher through a compromised barrier, though azelaic acid's systemic absorption is generally low regardless of age (plasma levels after topical application remain close to endogenous baseline). Second, and more clinically relevant, the risk of stinging, burning, and peeling is meaningfully higher in postmenopausal skin. A woman who tolerated 20% azelaic acid cream at 45 may find it intolerable at 68.

Rosacea in Women Over 65: The Evidence Is Strongest Here

Rosacea is the indication where the evidence for azelaic acid in older women is most solid. The condition is extremely common in postmenopausal women. Estrogen withdrawal removes a degree of vascular tone regulation, which contributes to the flushing and persistent erythema that define rosacea subtypes 1 and 2.

Two key trials established 15% azelaic acid gel for rosacea: the IND-20 and IND-21 trials, which enrolled adults across a wide age range and showed statistically significant reductions in inflammatory lesion counts and erythema scores compared to vehicle. These trials did not publish subgroup analyses for women over 65 specifically, which is a real evidence gap.

Rosacea Subtypes and Which Respond

Not all rosacea subtypes respond equally to azelaic acid:

• Erythematotelangiectatic rosacea (ETR, subtype 1): Azelaic acid has some anti-erythema effect but is not the primary agent for persistent background redness. Brimonidine or oxymetazoline are more effective for vasoconstriction.
• Papulopustular rosacea (PPR, subtype 2): This is where azelaic acid shines. Inflammatory papules and pustules respond well, and the anti-inflammatory mechanism is well matched to the pathophysiology.
• Phymatous rosacea (subtype 3): Azelaic acid has no established role here.
• Ocular rosacea (subtype 4): Topical azelaic acid is not used for this subtype; lid hygiene and oral doxycycline are standard.

Women over 65 with PPR are the strongest candidates for azelaic acid therapy among the rosacea subtypes.

What Happens With Long-Term Use in Older Skin

There is no published safety signal specific to older women for long-term azelaic acid use. The general understanding, based on its mechanism (it does not cause atrophy, does not affect collagen synthesis negatively, and is not phototoxic), is that it is safe for extended use. Dermatologists frequently continue it for years without dose reduction. The recommendation in postmenopausal skin is to pair it consistently with a bland emollient or a ceramide-containing moisturizer to offset the drying effect.

Off-Label Use for Hyperpigmentation and Melasma in Postmenopausal Women

Clinicians at WomanRx have identified a practical three-tier framework for evaluating which postmenopausal women are best suited to azelaic acid as a first-line, second-line, or adjunct depigmenting agent, based on skin barrier status, degree of pigmentation, and prior treatment history.

Tier 1 (first-line candidate): Women with mild-to-moderate melasma, new or worsening post-menopausal, who have not previously used prescription depigmenting agents and who have sensitive or barrier-compromised skin. Azelaic acid 15% gel is preferred over 20% cream in this group because the gel formulation is lighter and less occlusive on already-low-sebum skin.

Tier 2 (second-line or adjunct): Women who tried hydroquinone 4% and experienced ochronosis, paradoxical darkening, or intolerable irritation. Azelaic acid is a reasonable switch. Combining it with a low-potency retinoid (adapalene 0.1% or tretinoin 0.025%) can improve efficacy, but this combination requires very gradual introduction in postmenopausal skin and a dermatologist's supervision.

Tier 3 (adjunct to procedural care): Women who have had laser treatment (Q-switched Nd:YAG, IPL, or fractional CO2) for solar lentigines or melasma. Azelaic acid applied after laser-treated skin has fully healed can help suppress melanocyte reactivation and reduce recurrence. This is entirely off-label but mechanistically sound.

Melasma: What the Data Actually Shows

The most cited study supporting azelaic acid 20% cream for melasma compared it to hydroquinone 2% (not the standard 4%) in a randomized trial published in the Journal of the American Academy of Dermatology, finding similar efficacy at 24 weeks. A subsequent meta-analysis examining topical agents for melasma confirmed azelaic acid's activity but noted that hydroquinone 4% still outperforms it when skin can tolerate the stronger agent.

The takeaway for a woman over 65: azelaic acid is not the most potent option, but it may be the most appropriate option when barrier compromise, chronic irritation history, or concerns about ochronosis with long-term hydroquinone are factors. No trial has enrolled primarily postmenopausal women for this indication.

Solar Lentigines: A Different Beast

Solar lentigines ("age spots") are distinct from melasma mechanistically, though they share tyrosinase-mediated melanin overproduction. Azelaic acid's tyrosinase inhibition is relevant, but the evidence for it specifically in solar lentigines is sparse. A small open-label study published in the early 1990s showed modest lightening of facial lentigines with 20% cream. More recent options like tranexamic acid and cysteamine cream have shown competitive efficacy in this indication with equally favorable safety profiles, and a dermatologist may prefer those agents specifically for lentigines in older women.

Dosing and Formulation Decisions for Women Over 65

Standard dosing from the FDA-approved labeling is twice daily application to the affected area. In practice, many dermatologists start older women at once daily for the first four to six weeks, then increase to twice daily if tolerated. This is not studied in a formal dose-finding trial for this age group; it is clinical practice based on known skin fragility.

Gel vs. Cream: Which Formulation Works Better in Postmenopausal Skin

• 15% azelaic acid gel (Finacea): Water-based. Less occlusive. Better for women with any residual oiliness or who live in humid climates. The alcohol-free formulation is preferred in women with rosacea-prone skin that reacts to alcohol.
• 20% azelaic acid cream (Azelex): Cream base. More emollient. On its face, this sounds better for dry postmenopausal skin, but the 20% concentration carries higher irritation risk, which may offset the moisturizing benefit of the cream base.

Most clinicians prescribing for older women with dry or barrier-compromised skin choose 15% gel with an added moisturizer rather than 20% cream alone. The lower concentration is gentler. The moisturizer addresses dryness independently.

Generic azelaic acid 15% gel became available in the US after Finacea's exclusivity period ended, and it is considerably cheaper. The generics have the same active ingredient concentration and have been bioequivalent-tested, though the excipient mix differs slightly. For women with very reactive skin, switching from brand to generic (or vice versa) occasionally triggers irritation from the excipient difference, not the active ingredient.

Application Technique Matters More in Aging Skin

The standard instruction is a thin layer to clean, dry skin. In older women, two additional steps improve tolerability:

1. Apply to skin that is fully dry after washing (at least two to three minutes, not immediately after patting dry). Wet skin increases irritation from azelaic acid by enhancing penetration through a temporarily disrupted barrier.
2. Apply a ceramide-containing moisturizer either 10 minutes before (as a barrier primer) or 10 minutes after azelaic acid, not simultaneously. Layering them immediately dilutes the active and reduces efficacy at the treatment site.

Side Effects: What to Expect and What Signals a Problem

The most common adverse effects in all age groups are local: stinging, burning, tingling, and pruritus. In the key rosacea trials, approximately 29% of patients reported stinging or burning with 15% gel. That figure was derived from a mixed-age adult population. In postmenopausal skin, the rate is likely higher, though no published subgroup data confirms this.

Erythema and scaling occur in a smaller proportion. These usually resolve within two to four weeks of starting treatment as the skin accommodates. If they persist beyond four weeks, the once-daily approach or a formulation switch is warranted.

Contact dermatitis is rare but documented. True allergic contact sensitization to azelaic acid is uncommon; more often, a reaction is irritant contact dermatitis from the vehicle excipients (propylene glycol, benzoic acid depending on formulation). Patch testing can differentiate them if the reaction is severe or recurrent.

Hypopigmentation is a theoretical concern given the drug's selective melanocyte toxicity, but in clinical practice at therapeutic concentrations, significant hypopigmentation is rare and typically occurs only in darker skin phototypes (Fitzpatrick IV-VI) with prolonged use. Women with Fitzpatrick I-III skin (which describes the majority of women over 65 of European ancestry experiencing photoaging) have very low hypopigmentation risk.

When to Stop

Stop azelaic acid and contact a clinician if you notice:

• Spreading rash beyond the application area
• Facial swelling or difficulty breathing (these signal a systemic allergic reaction, which is rare but requires immediate care)
• Worsening rather than stable or improving redness after six weeks of consistent use
• Skin that feels raw or broken in the treatment area

Hormonal Context: How Menopause Changes the Azelaic Acid Story

This section matters and is largely absent from competitor discussions of azelaic acid.

Estrogen has direct effects on skin melanocyte regulation. Estrogen receptors alpha and beta are expressed on melanocytes, and estrogen modulates both basal melanin production and the melanocyte response to UV exposure. When estrogen drops at menopause, this regulation loosens. The result is that postmenopausal melanocytes are, on average, more reactive to UV stimulation and slower to return to baseline after a pigmentary insult.

This is why melasma that seemed controlled in the perimenopausal years can flare dramatically in the first two to three years of post-menopause, even without new sun exposure triggers. It is also why treatment is harder: you are managing a hormonally disinhibited system.

Azelaic acid addresses the downstream enzyme (tyrosinase) rather than the upstream hormonal dysregulation. It is effective at the enzyme level regardless of estrogen status. What changes is that without the regulatory influence of estrogen, you may need longer treatment durations to achieve the same result, and maintenance therapy (continuing at least once-daily application) is more important than in younger women.

Menopausal hormone therapy (MHT) does affect this picture. Some observational data suggests MHT users experience less age-related hyperpigmentation progression, though MHT is not prescribed for a dermatologic indication. Women already on systemic estrogen therapy may find azelaic acid works more predictably because their hormonal environment is more stable. Women choosing not to use MHT, or who have contraindications to it, need to understand that the pigmentary instability of untreated post-menopause may mean longer treatment timelines and more consistent sun protection discipline.

Sun protection is not optional when using azelaic acid for pigmentation. It is a co-requirement. Broad-spectrum SPF 30 or higher, applied daily regardless of cloud cover, is the baseline. Without it, UV-driven melanocyte activation will outpace any tyrosinase inhibition from the drug.

Interactions With Other Skincare Agents Common in Women Over 65

Women over 65 often use multiple topical agents simultaneously. A few combinations require thought:

With tretinoin: Combining azelaic acid with tretinoin increases efficacy for both hyperpigmentation and rosacea but also substantially increases irritation risk. In older skin, the standard approach is to alternate: tretinoin at night, azelaic acid in the morning, with moisturizer as a buffer on both ends. Starting tretinoin at the lowest available concentration (0.025% cream) before adding azelaic acid is prudent.

With benzoyl peroxide: Azelaic acid for rosacea-related papulopustules can be combined with benzoyl peroxide in women who have mixed rosacea and gram-negative folliculitis, but benzoyl peroxide is highly drying and the combination often proves too irritating for postmenopausal skin. Sequential use (one in the morning, one at night, months apart) is safer than simultaneous application.

With oral doxycycline: This combination is common in PPR management. There is no pharmacokinetic interaction. The combination is considered additive in anti-inflammatory effect, and oral antibiotics are often used for the initial phase while azelaic acid provides maintenance.

With topical corticosteroids: Women over 65 sometimes use low-to-mid potency corticosteroids for perioral dermatitis, seborrheic dermatitis, or other facial conditions. Concurrent azelaic acid on the same area is generally fine for short durations, but prolonged corticosteroid use thins skin further, compounding the barrier fragility problem. The corticosteroid should be used for the shortest necessary duration.

With tranexamic acid (topical): An increasingly popular combination for melasma. No formal interaction data exists, but the mechanisms are complementary (tranexamic acid works on the plasminogen-UV pathway, azelaic acid on tyrosinase). Combining them does not appear to increase irritation meaningfully and may improve efficacy, though RCT evidence for the combination in postmenopausal women is absent.

Pregnancy and Lactation: Relevant Context for Women Over 65

For the large majority of women in the 65-and-older age group, pregnancy is not a consideration. A brief note remains appropriate because some women in early post-menopause who are prescribed azelaic acid may still be in a peri-to-post transition where pregnancy, however unlikely, is worth addressing, and because clinicians and pharmacists reviewing treatment plans need complete safety framing.

Azelaic acid carries FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, and no adequate well-controlled studies in pregnant women exist at the 15-20% prescription concentrations. Given very low systemic absorption from topical application, fetal exposure is expected to be minimal. Most dermatologists consider it one of the safer options for pregnant women who require treatment for acne or rosacea, though the preference in pregnancy is to use only what is necessary and for the shortest duration.

Lactation transfer: systemic absorption of topically applied azelaic acid is negligible. Endogenous azelaic acid is present in human milk. No adverse effects on nursing infants have been reported. Applying it to the chest or breast area while nursing is not recommended (to avoid infant oral contact), but facial application is generally considered low risk.

For women over 65, contraception is not a prescribing requirement for azelaic acid. Azelaic acid is not teratogenic and does not require contraception counseling as part of its REMS or prescribing information, unlike isotretinoin.

Who This Is Right For (and Who Should Be Cautious)

Good Candidates

• Women over 65 with papulopustular rosacea who have not responded to metronidazole alone or who want an alternative to antibiotic-based therapy
• Women with postmenopausal melasma who have had ochronosis with hydroquinone or who cannot tolerate hydroquinone's irritation
• Women with mild-to-moderate post-inflammatory hyperpigmentation in the setting of frequent rosacea flares
• Women who want a non-phototoxic option (unlike some acids and retinoids, azelaic acid does not increase photosensitivity, though SPF is still essential)
• Women with Fitzpatrick I-III skin and isolated facial hyperpigmentation

Women Who Should Proceed With Extra Caution

• Women with severely compromised skin barrier (active eczematous skin, perioral dermatitis being actively treated with corticosteroids, or a history of strong reactions to cosmetic acids)
• Women on oral immunosuppressants or biologics for other conditions (the skin's inflammatory signaling is altered and irritation responses may be unpredictable)
• Women with Fitzpatrick IV-VI skin phototypes using for hyperpigmentation: the risk of paradoxical hypopigmentation, while still low, is higher, and a dermatologist experienced with skin of color should supervise treatment

A Realistic Expectation-Setting Conversation

The American Academy of Dermatology notes that visible improvement in hyperpigmentation with azelaic acid typically requires 12 to 24 weeks of consistent twice-daily use. In postmenopausal women, who face ongoing hormonal instability and higher cumulative UV damage, realistic timelines may lean toward the longer end. Stopping after six weeks because results are not dramatic is the most common reason for perceived treatment failure.